RNA-Seq: Principles, Methods, Computational Analysis

Published on :

This 5-Day workshop combines a unique mix of hands-on wet bench and electronic laboratory experiences together with a series of lectures spanning an introduction to the concepts of RNA sequencing [….]

Single Cell RNA-Seq

Published on :

This in-depth lecture and hands-on laboratory workshop (wet lab & in silica) is ideal for those research and bench scientists who are interested in a comprehensive introduction to single cell [….]

Python for Research Scientists

Published on :

Python is a popular scripting language that is used by data professionals because of its many-popular statistical libraries. The live remote three-day lecture and hands-on computer-based laboratory workshop is designed [….]

Multiplex Immunofluorescence in Immune Oncology, Workshop & Symposium

Published on :

This four day program is divided into a two-day symposium with lectures presented by world class scientists in the field of immuno-oncology and with representation by all the main multiplex [….]

Flow Cytometry: Principles, Methods and Applications

Published on :

This four day program is ideal for those who are looking for an in-depth, hands-on introduction to Flow Cytometry. Developed and taught by active researchers, this workshop will focus on [….]

miRecule Inc. closes $5.7 M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy

Published on :

miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.

Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer

Published on :

Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer Descartes-11 specifically designed to integrate into standard treatment regimen for newly diagnosed multiple myeloma without [….]